Aldeyra Therapeutics (ALDX) Accounts Payables (2013 - 2026)
Aldeyra Therapeutics (ALDX) posted Accounts Payables of $141356.0 for Q1 2026, down 10.79% on a QoQ basis from $158461.0 in Q4 2025, and down 59.16% year-over-year from $346146.0 in Q1 2025.
Aldeyra Therapeutics (ALDX) Accounts Payables (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics' Accounts Payables history runs 14 years deep, the most recent figure standing at $141356.0 for Q1 2026.
- Quarterly Accounts Payables fell 59.16% year-over-year to $141356.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $141356.0 (down 59.16% YoY) and the FY2025 annual result came in at $158461.0, down 12.19% from the prior year.
- Accounts Payables was $141356.0 for Q1 2026 at Aldeyra Therapeutics, down from $158461.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $2.4 million in Q1 2022 and bottomed at $13423.0 in Q3 2025.
- A 5-year average of $555889.4 and a median of $264225.0 in 2022 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2023 — Accounts Payables jumped 901.35% — and 2025, when it tumbled 92.82%.
- Aldeyra Therapeutics' Accounts Payables stood at $133625.0 in 2022, then soared by 901.35% to $1.3 million in 2023, then sank by 86.51% to $180453.0 in 2024, then decreased by 12.19% to $158461.0 in 2025, then retreated by 10.79% to $141356.0 in 2026.
- Business Quant data shows ALDX's Accounts Payables at $141356.0 in Q1 2026, $158461.0 in Q4 2025, and $13423.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 5.74 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 10.62 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 8.64 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 423.55 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 489.30 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 1.03 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 1.52 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 80.54 Mn |
| 10 | Aldeyra Therapeutics | 95.00 Mn | 95.00 Mn | - | 141,356.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 141,356.00 |
| Dec 31, 2025 | 158,461.00 |
| Sep 30, 2025 | 13,423.00 |
| Jun 30, 2025 | 1.46 Mn |
| Mar 31, 2025 | 346,146.00 |
| Dec 31, 2024 | 180,453.00 |
| Sep 30, 2024 | 186,919.00 |
| Jun 30, 2024 | 254,434.00 |
| Mar 31, 2024 | 280,299.00 |
| Dec 31, 2023 | 1.34 Mn |
| Sep 30, 2023 | 247,194.00 |
| Jun 30, 2023 | 270,816.00 |
| Mar 31, 2023 | 429,685.00 |
| Dec 31, 2022 | 133,625.00 |
| Sep 30, 2022 | 1.31 Mn |
| Jun 30, 2022 | 264,225.00 |
| Mar 31, 2022 | 2.44 Mn |
| Dec 31, 2021 | 1.02 Mn |
| Sep 30, 2021 | 467,932.00 |
| Jun 30, 2021 | 1.09 Mn |